Serum Catestatin as a Novel Biomarker of Cardiometabolic Risk among Diabetic Children | ||||
| The Egyptian Journal of Hospital Medicine | ||||
| Article 178, Volume 91, Issue 1, April 2023, Page 4903-4909 PDF (594.74 K) | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/ejhm.2023.301576 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
| Soad Shedeed; Yasmeen El-Sayed Ibrahim; Alshymaa A. Ahmed; Ahmed Elhewala | ||||
| Abstract | ||||
| Background: Along with decreased sympatho-adrenal flow, catestatin has a number of cardiovascular effects. Reduced plasma catestatin levels could be a sign of a predisposition to develop metabolic and hypertensive diseases. Aim and objectives: To assess the function of catestatin in cardiometabolic risk assessment among diabetic children. Subjects and methods: This case-control study was carried out on 108 children at Pediatrics Department, Zagazig University Hospital. Children were divided into 2 groups: (Group A): Case group 54 children with diabetes, (Group B): Control group 54 apparent healthy children at same sex and age. Every infant was subjected to serum catestatin concentrations measurement using ELISA Kit. Result: Median Catestatin in diabetic group was 8.35 ng/ml (6.16 – 17.41) while that for Control group was 11.19 ng/dl(7.42 -16.56), the difference was statistically significant(p < 0.05). Conclusion: Serum Catestatin was related to diabetes and it cannot be considered as a good biomarker of cardio metabolic risk among diabetic children. Further larger scale studies are needed to confirm our results. | ||||
| Keywords | ||||
| heart; blood pressure; coronary artery disease; and metabolic; catestatin | ||||
|
Statistics Article View: 80 PDF Download: 172 |
||||
